PDP
New Member
Anxiety & Depression - Steroids and the Brain
Summary: The major neurotransmitters are Serotonin, Dopamine and Norepinephrine. Fluctuations or a deficiency in some or all of these neurotransmitters are thought to be a primary cause of depression, anxiety, panic, aggression and other mood disorders. There is convincing evidence that the abuse of Androgenic Anabolic Steroids can alter the balance of these substances which may contribute to these mental conditions. The fluctuations attributed to AAS use may contribute to these conditions via a direct mechanism or may elicit a feedback response that may invoke these conditions during or after cessation of use of AAS.
Bottom line: AAS have a very high likelihood of increasing the severity or setting off these mood disorders in those genetically susceptible.
Increased dopaminergic and 5-hydroxytryptaminergic activities in male rat brain following long-term treatment with anabolic androgenic steroids.
Thiblin I, Finn A, Ross SB, Stenfors C.
Department of Forensic Medicine, Karolinska Institute, Stockholm, Sweden.
1. The effects of treating groups of rats with four different anabolic androgenic steroids (AAS) (testosterone, nandrolone, methandrostenolone, and oxymetholone) on 5-hydroxytryptamine (5-HT) and dopamine (DA) neurones in different brain regions were examined. The AAS was injected six times with 1 week's interval and the rats were sacrificed 2 days after the final injection. 5-HT and its metabolite 5-hydroxyindoleacetic acid (5-HIAA), DA and its metabolites 3,4-dihydroxyphenylacetic acid (DOPAC) and homovanillic acid (HVA) were measured. The effect on DA and 5-HT synthesis rate was analysed as the accumulation of 3,4-dihydroxyphenyl-alanine (DOPA) and 5-hydroxytryptophan (5-HTP), respectively, after inhibition of the amino acid decarboxylase with NSD-1015 (3-hydroxy-benzylhydrazine dihydrochloride). Additionally, the monoamine oxidase (MAO) activity was analysed in the hypothalamus. 2. The DOPAC + HVA/DA ratio was increased in the striatum in all treatment groups. However, the synthesis rate of DA was significantly increased only in the methandrostenolone treated group. 3. The 5-HIAA/5-HT ratio was increased in all treatment groups in the hippocampus, in the frontal cortex in the methandrostenolone-treated animals and in the hypothalamus in the testosterone- and oxymetholone-treated rats, while the 5-HT synthesis rate was not affected by the AAS-treatments. 4. The MAO-A activity was increased in the oxymetholone-treated rats while the other treatment groups were unaffected. The MAO-B activity was not changed. 5. The results indicate that relatively high doses of AAS increase dopaminergic and 5-hydroxytryptaminergic metabolism in male rat brain, probably due to enhanced turnover in these monaminergic systems.
Summary: The major neurotransmitters are Serotonin, Dopamine and Norepinephrine. Fluctuations or a deficiency in some or all of these neurotransmitters are thought to be a primary cause of depression, anxiety, panic, aggression and other mood disorders. There is convincing evidence that the abuse of Androgenic Anabolic Steroids can alter the balance of these substances which may contribute to these mental conditions. The fluctuations attributed to AAS use may contribute to these conditions via a direct mechanism or may elicit a feedback response that may invoke these conditions during or after cessation of use of AAS.
Bottom line: AAS have a very high likelihood of increasing the severity or setting off these mood disorders in those genetically susceptible.
Increased dopaminergic and 5-hydroxytryptaminergic activities in male rat brain following long-term treatment with anabolic androgenic steroids.
Thiblin I, Finn A, Ross SB, Stenfors C.
Department of Forensic Medicine, Karolinska Institute, Stockholm, Sweden.
1. The effects of treating groups of rats with four different anabolic androgenic steroids (AAS) (testosterone, nandrolone, methandrostenolone, and oxymetholone) on 5-hydroxytryptamine (5-HT) and dopamine (DA) neurones in different brain regions were examined. The AAS was injected six times with 1 week's interval and the rats were sacrificed 2 days after the final injection. 5-HT and its metabolite 5-hydroxyindoleacetic acid (5-HIAA), DA and its metabolites 3,4-dihydroxyphenylacetic acid (DOPAC) and homovanillic acid (HVA) were measured. The effect on DA and 5-HT synthesis rate was analysed as the accumulation of 3,4-dihydroxyphenyl-alanine (DOPA) and 5-hydroxytryptophan (5-HTP), respectively, after inhibition of the amino acid decarboxylase with NSD-1015 (3-hydroxy-benzylhydrazine dihydrochloride). Additionally, the monoamine oxidase (MAO) activity was analysed in the hypothalamus. 2. The DOPAC + HVA/DA ratio was increased in the striatum in all treatment groups. However, the synthesis rate of DA was significantly increased only in the methandrostenolone treated group. 3. The 5-HIAA/5-HT ratio was increased in all treatment groups in the hippocampus, in the frontal cortex in the methandrostenolone-treated animals and in the hypothalamus in the testosterone- and oxymetholone-treated rats, while the 5-HT synthesis rate was not affected by the AAS-treatments. 4. The MAO-A activity was increased in the oxymetholone-treated rats while the other treatment groups were unaffected. The MAO-B activity was not changed. 5. The results indicate that relatively high doses of AAS increase dopaminergic and 5-hydroxytryptaminergic metabolism in male rat brain, probably due to enhanced turnover in these monaminergic systems.
